I would speculate that the shape of the virus is not as important as the shape and flexibility of the host cell, and more importantly for investors, the mimic micelle that the virus will attach to.
Is the host cell, the human cell to which Ebola attaches, shaped to complement Ebola? Is the NanoViricide micelle shape in such a way to mimic the host cell? Designing a mimic that replicates the vulnerable host cell is the challenge.
Are the attachment proteins on the host cell optimized to encourage Ebola attachment? Is the viricide Ebola-specific coating designed to mimic the host cell attachment characteristics?
It is Ebola that accommodates the existing characteristics of the host cell. Nanoviricides' micelle and it's chemical coating is designed to mimic the characteristics of the host cell. Will the Ebola virus bind to the mimic? If Dr. Diwan has designed Ebolacide correctly Ebola will attach regardless of its unique shape and cell characteristics. The peculiar shape of the Ebola virus does not prevent it from flexing and bending to attach to a host cell. Therefore Ebola has the capacity to bend and flex to accommodate the shape and characteristics of EbolaCide.
NNVC has been called a lifestyle company, management has been disparaged, every misstep and delay has been catalogued and cited to beat the stock price down. Supporters have countered and cajoled to keep the price up. (To the extant that iHub chatter can effect the price.)
In recent months NanoViricide has put their science on the line. BASi has preformed preliminary FluCide Tox testing.
USAMRIID is conducting EbolaCide efficacy testing.
Before Q2 is over Bears and Bulls will have these provisional 3rd party results to determine their investment position.
